摘要目的: 探讨上皮性卵巢癌(Epithelial Ovarian Cancer,EOC)初治患者生存结局的影响因素。方法: 回顾性分析山东省临沂市肿瘤医院于2018年1月至2020年12月收治的219例可随访的EOC初治患者,记录患者的年龄、身高、体重、确诊时间、手术时间、手术范围、病理学结果、血清糖类抗原125(carbohydrate antigen 125,CA125)变化情况、初始治疗时的化疗次数及时间、初次治疗后的初次复发时间等信息。分析并比较患者的生存结局。结果: 219例EOC初治患者平均年龄56.0岁(25~81岁)。中位随访时间62个月(4~81个月)。患者的国际妇产科联盟(Federation International of Gynecology and Obstetrics,FIGO)分期、分化程度、侧别、是否行肿瘤细胞减灭术、是否行盆腔淋巴结清扫术、初次治疗总化疗次数、先期化疗次数、有无腹水、血清CA125是否于术后化疗≤3程降至正常范围以及初次治疗后初次复发间隔是否≤12个月均为EOC初治患者生存结局的影响因素,差异有统计学意义(均P＜0.05)。多因素COX回归分析显示,FIGO分期、是否行肿瘤细胞减灭术、血清CA125是否于术后化疗≤3程降至正常、初次复发间隔是否≤12个月均为EOC初治患者生存结局的独立影响因素(均P<0.05)。结论: 上皮性卵巢癌患者大多数确诊时为晚期,5年生存率低。提高早期上皮性卵巢癌的诊断率、尽早施行满意的肿瘤细胞减灭术、推迟上皮性卵巢癌患者初次治疗后的初次复发时间可改善其生存结局。
Abstract：Objective: To discuss the influencing factors of survival outcomes in patients with epithelial ovarian cancer(EOC) after initial treatment. Methods: A total of 219 patients with EOC, who were eligible for follow-up,were admitted to Linyi Tumor Hospital from Jan. 2018 to Dec. 2020 Clinical datas, such as the age, height, weight, the time of diagnosis, surgery time, surgical scope, pathological results, changes in serum carbohydrate antigen 125(CA125), the frequency and time of chemotherapy, and the time of first recurrence after initial treatment, above of the subjects were recorded. Calculate and compare the survival outcomes of these patients. Results: The average age of the 219 newly treated patients with epithelial ovarian cancer is 56.0 years (25~81 years old). The median follow-up time was 71 months (4~99 months). The FIGO stage, degree of differentiation, tumor side, underwent cytoreductive surgery or not, pelvic lymphadenectomy or not, chemotherapy frequency in initial treatment, neoadjuvant chemotherapy (NACT) frequency, ascites or not, CA125 decreased to normal within three courses of chemotherapy postoperatively or not, the recurrence interval after initial treatment was less than 12 months or not, are statistically significant factors affecting the survival outcome of EOC patients after initial treatment (P＜0.05). According to the results of multivariate COX regression analysis, FIGO stage, underwent cytoreductive surgery or not, CA125 decreased to normal within three courses of chemotherapy postoperatively or not, and whether the recurrence interval after initial treatment was ≤ 12 months, are all independent risk factors affecting the survival outcome of EOC patients after initial treatment (P＜0.05). Conclusion: Most patients with EOC are diagnosed in advanced stages, with a low 5-year survival rate. Improving diagnostic rate of early ovarian cancer, executing satisfactory cytoreductive surgery as early as possible, and postponing the recurrence time after initial treatment can improve the prognosis of patients with ovarian cancer.
左东华, 张洪云, 钟艳, 李秀敏, 刘蓓蓓. 上皮性卵巢癌患者治疗后生存的影响因素[J]. 河北医学, 2025, 31(5): 853-858.
ZUO Donghua, et al. The Influencing Factors of Survival Outcomes in Patients with Epithelial Ovarian Cancer After Treatment. HeBei Med, 2025, 31(5): 853-858.
[1] 沈丽娜,臧荣余.卵巢癌一级预防研究进展[J].肿瘤防治研究,2023,50(3):224-228. [2] 王萍,陈礼梅,张丽.术前外周血单核细胞与淋巴细胞比值联合纤维蛋白原对上皮性卵巢癌患者预后的预测价值[J].中国医师进修杂志,2022,45(4):326-330. [3] 曹冬焱.卵巢癌规范化诊疗与进展[J].中国临床医生杂志,2023,51(3):268-271. [4] 杜彬.卵巢癌的病理分型与精准治疗[J].上海医学,2023,46(11):745-749. [5] 郭勤浩,吴小华.2022年度卵巢癌诊治进展[J].肿瘤综合治疗电子杂志,2023,9(2):110-118. [6] Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer[J]. Nat Rev Clin Oncol,2024,21(5):389-400. [7] 王新娇,任芳,李彩瑜,等.血清VEGF、TAP、CA125及HE4检测在卵巢上皮性癌诊断中的临床价值[J].医药论坛杂志,2023,44(12):47-53. [8] 韩晴,何爱琴,李咏,等.血清Stathmin、TFF3与上皮性卵巢癌患者初始肿瘤细胞减灭术治疗结局和术后复发的关系[J].国际检验医学杂志,2023,44(23):2848-2853. [9] You B, Purdy C, Copeland LJ, et al. Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study[J].Clin Oncol. 2022,40(34):3965-3974. [10] Sambasivan S. Epithelial ovarian cancer: review article[J]. Cancer Treat Res Commun,2022(33):100629.
2025, Vol. 31 
冀公网安备13080202000786号